AR128847A1 - Forma de sal cristalina de un inhibidor de shp2 - Google Patents

Forma de sal cristalina de un inhibidor de shp2

Info

Publication number
AR128847A1
AR128847A1 ARP230100698A ARP230100698A AR128847A1 AR 128847 A1 AR128847 A1 AR 128847A1 AR P230100698 A ARP230100698 A AR P230100698A AR P230100698 A ARP230100698 A AR P230100698A AR 128847 A1 AR128847 A1 AR 128847A1
Authority
AR
Argentina
Prior art keywords
salt form
crystalline salt
shp2 inhibitor
crystalline
compositions
Prior art date
Application number
ARP230100698A
Other languages
English (en)
Spanish (es)
Inventor
Katie Keaton Brown
Connor James Cowdrey
Aaron Keith Goodwin
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR128847A1 publication Critical patent/AR128847A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP230100698A 2022-03-23 2023-03-22 Forma de sal cristalina de un inhibidor de shp2 AR128847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263323005P 2022-03-23 2022-03-23

Publications (1)

Publication Number Publication Date
AR128847A1 true AR128847A1 (es) 2024-06-19

Family

ID=85724850

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100698A AR128847A1 (es) 2022-03-23 2023-03-22 Forma de sal cristalina de un inhibidor de shp2

Country Status (11)

Country Link
US (1) US20250214966A1 (enExample)
EP (1) EP4496629A1 (enExample)
JP (1) JP2025509818A (enExample)
KR (1) KR20240163705A (enExample)
CN (1) CN119095836A (enExample)
AR (1) AR128847A1 (enExample)
AU (1) AU2023238523B2 (enExample)
CA (1) CA3256136A1 (enExample)
MX (1) MX2024011603A (enExample)
TW (1) TW202346282A (enExample)
WO (1) WO2023180898A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
JP2025509818A (ja) 2025-04-11
TW202346282A (zh) 2023-12-01
WO2023180898A1 (en) 2023-09-28
US20250214966A1 (en) 2025-07-03
CA3256136A1 (en) 2023-09-28
CN119095836A (zh) 2024-12-06
KR20240163705A (ko) 2024-11-19
AU2023238523B2 (en) 2025-10-30
AU2023238523A1 (en) 2024-08-22
MX2024011603A (es) 2024-09-30
EP4496629A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
CL2020002748A1 (es) Inhibidores de cinasa dependientes de ciclina
MX2024013469A (es) Compuestos heterocíclicos y usos de estos
BR112023019479A2 (pt) Forma cristalina de um inibidor de shp2
DOP2023000208A (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
MX2021008645A (es) Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk).
UY33328A (es) "5,7-SUSTITUIDO-IMIDAZOL[1,2-c]PIRIMIDINAS"
ECSP099803A (es) Derivados de bencimidazol
SV2011003853A (es) Compuestos organicos
UY39303A (es) Inhibidores de mutación her2
CL2023001859A1 (es) Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas
ECSP12011638A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
MX2021010321A (es) Compuestos macrociclicos.
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
PE20250664A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CO2024011199A2 (es) Composiciones y métodos para inhibir el factor b del complemento
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
MX347040B (es) Inhibidores de tirosina-cinasas.
DOP2025000216A (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa